# Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

> **NCT06544551** · PHASE3 · COMPLETED · sponsor: **Beijing Kawin Technology Share-Holding Co., Ltd.** · enrollment: 336 (actual)

## Conditions studied

- Chronic Hepatitis B Virus Infection

## Interventions

- **DRUG:** Peginterferon Alfacon-2
- **DRUG:** Peginterferon Alfacon-2 placebo

## Key facts

- **NCT ID:** NCT06544551
- **Lead sponsor:** Beijing Kawin Technology Share-Holding Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-28
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544551, "Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06544551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*